Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) ± ribavir...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Gilead Sciences
NCT06718530 · Hepatitis C Virus Infection
NCT06463912 · Hepatitis C Virus Infection
NCT05361603 · Hepatitis C, Transmission, Intravenous Drug Abuser, and more
NCT04677153 · Hepatitis C Virus Infection, Response to Therapy of
NCT05975216 · Hepatitis C Virus Infection
The Texas Liver Institute
San Antonio, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions